MedTrace Logo

CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)

NCT02047175 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2014-04-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the drug-drug interaction of CKD-346(Telmisartan/S-Amlodipine, Rosuvastatin)

Conditions

Interventions

DRUG

Telmisartan/S-Amlodipine

Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days

DRUG

Rosuvastatin

Rosuvastatin 20mg 1T PO, QD for 5days

DRUG

Telmisartan/S-Amlodipine + Rosuvastatin

Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days

DRUG

Telmisartan/S-Amlodipine + Rosuvastatin

Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Dong-seok Yim, professor · The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02047175 on ClinicalTrials.gov